2013 ACC/AHA控制血胆固醇降低成人动脉粥样硬化心血管风险指南的解读被引量：1

导出

摘要 2013年11月美国心脏病学会（ACC）和美国心脏协会（AHA）联合颁布了“控制血胆固醇降低成人动脉粥样硬化心血管风险指南”（简称新指南）。新指南在胆固醇的基本治疗理念与治疗策略方面有显著变化，放弃了特定的低密度脂蛋白胆固醇（LDL—C）的目标值，

作者杨茜岚鲁翔

机构地区南京医科大学第二附属医院

出处《实用老年医学》 CAS 2014年第3期261-264,共4页 Practical Geriatrics

关键词动脉粥样硬化心血管风险血胆固醇 ACC AHA 新指南成人低密度脂蛋白胆固醇美国心脏病学会

分类号 R543.5 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献11

1Stone NJ, Robinson J, LichtensteinAH, et al.2013 ACC/ AHA guidelineon the treatment of blood cholesterolto reduce atheroscleroticcardiovascular risk in adults :a reportof the American College ofCardiology/ American HeartAssociation Task Force on PracticeGuidelines[J]. Circulation, 2013.(Epub ahead of print).
2National Cholesterol EducationProgram (NCEP) Expert Panel onDetection, Evaluation, and Treatmentof High Blood Cholesterol in Adult(Adult Treatment Panel Ⅲ). ThirdReport of National Cholesterol Educa-tion Program (NCEP) Expert Panelon Detection, Evaluation, and Treat-ment of High Blood Cholesterol inAdult ( Adult Treatment Panel Ⅲ)final report [J]. Circulation, 2002,106(25):3143-3421.
3Goff DC Jr, Lloyd-Jones DM,Bennett G, et al. 2013 ACC/ AHAguideline on the assessment of Cardi-ovascular risk: a report of the Ameri-can college of cardiology/ Americanheart association task force onpractice guidelines[J]. Circulation,2013.( Epub ahead of print).
4Cholesterol Treatment Trialists(CTT) Collaboration. Efficacy andsafety of more intensive lowering ofLDL cholesterol: a meta-analysis ofdata from 170 000 participants in 26randomised trials [ J ]. Lancet,2010, 376(9753): 1670-1681.
5Sakamoto T, Ogawa H. “Just make itlower” is an alternative stragegy oflipid-lowering therapy with statins ifJapanese patients[J]. Circ J, 2010,74(8): 1731-1741.
6Sattar N, Preiss D, Murray HM, etal. Statins and risk of incident diabe-tes: a collaborative meta-analysis ofrandomized statin trials [J]. Lancet,2010, 375(9716): 735-742.
7Ridker PM, Cook NR. Statins:newAmerican guidelines for prevention ofcardiovascular disease [ J]. Lancet,2013, 382(9907):1762-1765.
8Cilla DD Jr, Whitfield LR, GibsonDM, et al. Multiple-dose pharmaco-kinetic, pharmacodynamics, andsafety of atorvastatin, an inhibitor ofHMG-CoA reductase, in healthy sub-jects [ J ]. Clini Pharmacol Ther,1996,60(6):687-695.
9European Association forCardiovscular Prevention & Rehabili-tation, Reiner Z, Catapano AL, DeBacker G, et al. ESC/ EASGuidelines for the management ofdyslipidaemias: the task forces forthe management of dyslipidaemias ofthe European Society of Cardiology(ESC) and the European Atheroscle-rosis Society (EAS) [J]. Eur HeartJ,2011,32(14):1769-1818.
10Lee E, Ryan S, Birmingham B, etal. Rosuvastatin pharmacokinetics anpharmacogenetics in white an asiansubjects residing in the same envi-ronment[J]. Clin Pharmacol Ther,2005,78(4):330-341.